title: Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study.
abstract: BACKGROUND
  Despite the prevalence and clinical significance of borderline personality disorder, its treatment remains understudied.
  
  
  OBJECTIVE
  To evaluate treatment with variably dosed olanzapine in individuals with borderline personality disorder.
  
  
  METHODS
  In this 12-week randomised, double-blind trial, individuals received olanzapine (2.5-20 mg/day; n=155) or placebo (n=159) (trial registry: NCT00091650). The primary efficacy measure was baseline to end-point change on the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) using last-observation-carried-forward methodology.
  
  
  RESULTS
  Both olanzapine and placebo groups showed significant improvements but did not differ in magnitude at end-point (-6.56 v. -6.25, P=0.661). Response rates (50% reduction in ZAN-BPD) were 64.7% with olanzapine and 53.5% with placebo (P=0.062); however, time to response was significantly shorter for olanzapine (P=0.022). Weight gain was significantly greater (2.86 v. -0.35 kg, P<0.001), with higher incidence of treatment-emergent abnormal high levels of prolactin for the olanzapine group.
  
  
  CONCLUSIONS
  Individuals treated with olanzapine and placebo showed significant but not statistically different improvements on overall symptoms of borderline personality disorder. The types of adverse events observed with olanzapine treatment appeared similar to those observed previously in adult populations.
authors.affiliation: Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN 55454, USA. scs@umn.edu
authors.forename: S Charles
authors.initials: SC
authors.lastname: Schulz
authors.forename: Mary C
authors.initials: MC
authors.lastname: Zanarini
authors.forename: Anthony
authors.initials: A
authors.lastname: Bateman
authors.forename: Martin
authors.initials: M
authors.lastname: Bohus
authors.forename: Holland C
authors.initials: HC
authors.lastname: Detke
authors.forename: Quynh
authors.initials: Q
authors.lastname: Trzaskoma
authors.forename: Yoko
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Daniel
authors.initials: D
authors.lastname: Lin
authors.forename: Walter
authors.initials: W
authors.lastname: Deberdt
authors.forename: Sara
authors.initials: S
authors.lastname: Corya
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D001883:Borderline Personality Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome; D015430:Weight Gain; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine